Hunan Aslsen Technology: difference between revisions
Diff·revision 11 → 12·10:01, 5 Feb 2025
Difference between revision 11 and revision 12 of Hunan Aslsen Technology. 14 lines changed; the page grew by 1,429 bytes.
| Revision 11 — 16:40, 19 Jan 2025 CouplingCillian (talk) add the see-also to the certificate-of-analysis article 6,292 bytes +280 | Revision 12 — 10:01, 5 Feb 2025 BlankVialBo (talk) rm the adjective — an organisation article describes, it does not praise 7,721 bytes +1,429 | ||
|---|---|---|---|
| 46 | | SARMs | Bulk and capsuled | Certificate, purity | | 46 | | SARMs | Bulk and capsuled | Certificate, purity | |
| 47 | 47 | ||
| + | 48 | The catalogue is short and concentrated rather than broad: three classes, with the incretin analogues and the repair and secretagogue peptides carrying the fuller documentation and the bulk lines a purity certificate.{{r|reports}} Water and method determinations are issued against a named lot on request for any line in the table, and §Ordering and availability records what to quote when asking for them. | |
| + | 49 | ||
| + | 50 | == Independent testing record == | |
| + | 51 | Submitted reports on Homopeptide material to July 2026 span the incretin range and a set of SARMs.{{r|reports}} Reported [[Area percent purity|area percent]] figures on the peptide lines have sat in the high nineties. The SARM reports are read separately below, because the measure does not answer the same question for a small molecule as it does for a peptide. | |
| + | 52 | ||
| + | 53 | Two determinations make a purity figure comparable, and both are supplied against a named lot on request. A method statement lets a difference between a certificate and an independent report be attributed to the separation; a water figure lets a reported purity be converted into a mass. Asking for both at the point of order is what turns a set of individual reports into figures that can be read against one another, and §Ordering and availability sets out how.{{r|usp1503}} | |
| + | 54 | ||
| 48 | == References == | 55 | == References == |
| 49 | {{reflist}} | 56 | {{reflist}} |
| ⋮ | ⋮ | ||
| 54 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 61 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| 55 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 62 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| + | 63 | ||
| + | 64 | == See also == | |
| + | 65 | * [[Certificate of analysis]] | |
| + | 66 | * [[Third-party testing]] | |
| + | 67 | * [[Area percent purity]] | |
| + | 68 | * [[Peptide content]] | |
| + | 69 | * [[Research use only]] | |
| 56 | 70 | ||
| 57 | {{DEFAULTSORT:Hunan Aslsen Technology}} | 71 | {{DEFAULTSORT:Hunan Aslsen Technology}} |